Atea Pharmaceuticals (AVIR) Price & Analysis

Compare

226 Followers

AVIR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.46 - $4.15

Previous CloseN/A

Volume180.19K

Average Volume (3M)282.21K

Market Cap

$241.25M

Enterprise Value-$76.98M

Total Cash (Recent Filing)$379.71M

Total Debt (Recent Filing)$1.25M

Price to Earnings (P/E)―

Beta0.76

Next Earnings

Nov 06, 2025

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.44

Shares Outstanding79,357,550

10 Day Avg. Volume169,090

30 Day Avg. Volume282,208

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)0.64

Price to Sales (P/S)0.00

P/FCF Ratio-2.08

Enterprise Value/Market Cap-0.32

Enterprise Value/Revenue-185.04

Enterprise Value/Gross Profit740.16

Enterprise Value/Ebitda0.51

Forecast

1Y Price Target

$6.00

Price Target Upside102.02% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAtea's treatment is considered the best-in-class pan-genotypic regimen for hepatitis C cure, focusing on a short eight-week treatment duration with low potential for drug-drug interactions.

Financial PositionStrong financial position with $425.4M in cash, extending runway into 2028.

Investor EnthusiasmPositive investigator enthusiasm and engagement fuel robust enrollment.

Bears Say

Global Trial DelaysThe management is running a second global Ph3 trial outside North America, which is expected to begin in mid-2025.

Net LossAtea reported a net loss of $37.2 million, or a loss of $0.44 per share.

Transition ChallengesAtea transitions into an HCV pure play, holding an optimistic view on the outcome of the Phase III study.

Atea Pharmaceuticals News

Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress

Atea Pharmaceuticals, Inc. (($AVIR)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

AVIR

Atea Pharmaceuticals Advances in HCV Treatment Development

Atea Pharmaceuticals, Inc. ( ($AVIR) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

AVIR

Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial

Atea Pharmaceuticals (AVIR) announced that the first patient was dosed in the global Phase 3 C-FORWARD trial evaluating...

3M ago

AVIR

Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting

Atea Pharmaceuticals ( ($AVIR) ) has shared an update. On June 20, 2025, Atea Pharmaceuticals held its 2025...

3M ago

AVIR

Atea Pharmaceuticals Advances HCV Treatment Trials

Atea Pharmaceuticals, Inc. ( ($AVIR) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

AVIR

AVIR Upcoming Earnings Report: What to Expect?

Atea Pharmaceuticals, Inc. (AVIR) is scheduled to report 1st quarter earnings on 05/12/2025, after the market closes. Regarding...

4M ago

AVIR

Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir

Atea Pharmaceuticals (AVIR) presented results from the full cohort of patients enrolled in its Phase 2 study evaluating...

4M ago

AVIR

Atea Pharmaceuticals to host hepatitis C virus KOL panel

Atea Pharmaceuticals (AVIR) will virtually host a hepatitis C virus key opinion leade panel discussion on topics related...

5M ago

AVIR

Atea Pharmaceuticals announces results from phase 2 study of bemnifosbuvir

Atea Pharmaceuticals (AVIR) announced that the full results from the Phase 2 clinical study of Atea’s regimen of...

5M ago

AVIR

Atea Pharmaceuticals Announces Board Changes and Share Buyback

An announcement from Atea Pharmaceuticals ( ($AVIR) ) is now available. On April 16, 2025, Atea Pharmaceuticals entered...

5M ago

AVIR

Atea Pharmaceuticals board authorizes $25M share repurchase program

Atea announced that its Board has authorized, and will promptly begin executing upon, the repurchase of up to...

5M ago

AVIR

Atea Pharmaceuticals says strategic alternatives process ‘ongoing’

The company said, “As previously announced on December 16, 2024, Atea engaged Evercore, a global independent investment bank,...

5M ago

AVIR

Atea Pharmaceuticals appoints Howard Berman to board of directors

Atea Pharmaceuticals (AVIR) announced the appointment of Howard Berman, Ph.D. to its Board of Directors. Dr. Berman will...

5M ago

AVIR

COYA

Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Atea Pharmaceuticals (AVIR) to $6 from $6.20 and keeps an...

5M ago

AVIR

AVIR FAQ

What was Atea Pharmaceuticals’s price range in the past 12 months?

Atea Pharmaceuticals lowest stock price was $2.46 and its highest was $4.14 in the past 12 months.

What is Atea Pharmaceuticals’s market cap?

Atea Pharmaceuticals’s market cap is $241.25M.

When is Atea Pharmaceuticals’s upcoming earnings report date?

Atea Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 48 days.

How were Atea Pharmaceuticals’s earnings last quarter?

Atea Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.025.

Is Atea Pharmaceuticals overvalued?

According to Wall Street analysts Atea Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atea Pharmaceuticals pay dividends?

Atea Pharmaceuticals does not currently pay dividends.

What is Atea Pharmaceuticals’s EPS estimate?

Atea Pharmaceuticals’s EPS estimate is -0.42.

How many shares outstanding does Atea Pharmaceuticals have?

Atea Pharmaceuticals has 79,357,550 shares outstanding.

What happened to Atea Pharmaceuticals’s price movement after its last earnings report?

Atea Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went down -2.312%.

Which hedge fund is a major shareholder of Atea Pharmaceuticals?

Currently, no hedge funds are holding shares in AVIR

Atea Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-32.38%

Trailing 12-Months

Asset Growth

-23.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atea Pharmaceuticals

Atea Pharmaceuticals (AVIR) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics. The company's primary area of focus is on oral direct-acting antiviral therapies to treat life-threatening viral infections, with its lead product candidate being AT-527 for the treatment of COVID-19.

Atea Pharmaceuticals (AVIR) Earnings & Revenues

Historic Earnings Reports

AVIR Company Deck

AVIR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call emphasized significant progress in clinical trials, a strong financial position, and positive market reception for their HCV program. However, challenges such as slower regulatory approvals outside North America and decreased interest income were noted. Despite these challenges, the overall sentiment is optimistic with a focus on future growth and market disruption.View all AVIR earnings summaries

AVIR Stock 12 Month Forecast

Average Price Target

$6.00

▲(102.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","2.5":"$2.5","5.5":"$5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.47,3.664615384615385,3.8592307692307695,4.053846153846154,4.248461538461538,4.443076923076923,4.637692307692308,4.832307692307692,5.026923076923077,5.2215384615384615,5.416153846153846,5.610769230769231,5.805384615384615,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.47,3.664615384615385,3.8592307692307695,4.053846153846154,4.248461538461538,4.443076923076923,4.637692307692308,4.832307692307692,5.026923076923077,5.2215384615384615,5.416153846153846,5.610769230769231,5.805384615384615,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.47,3.664615384615385,3.8592307692307695,4.053846153846154,4.248461538461538,4.443076923076923,4.637692307692308,4.832307692307692,5.026923076923077,5.2215384615384615,5.416153846153846,5.610769230769231,5.805384615384615,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.21,"date":1704067200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1706745600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.67,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.63,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >